Add to ORKGEfficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysi
OBJECTIVE: Although a reduced aflibercept (2.0mg) injection frequency relative to the approved dosin...
Intravitreal antivascular endothelial growth factor (VEGF) agents are widely used to treat ocular co...
Contains fulltext : 201379.pdf (publisher's version ) (Open Access
Purpose: This study was designed to assess the functional and anatomic outcomes of intravitreal afli...
Introduction Age-related macular degeneration (AMD) is an eye disease that can cause severe vision l...
International audienceThe current use of bevacizumab for age-related macular degeneration is mainly ...
PURPOSE Ranibizumab and aflibercept are both approved for the treatment of neovascular age-related ...
Noriko Miyamoto,1,2 Michiko Mandai,1,3 Hiroshi Kojima,1,2 Takanori Kameda,1,2 Masataka Shimozono,1,2...
Age-related macular degeneration (AMD) is a blinding disease placing considerable burden on society ...
Purpose. To evaluate the economic and clinical results of the aflibercept and ranibizumab angiogenes...
ABSTRACT Purpose: The present study compared the efficacy of aflibercept for neovascular age-relate...
Since the efficacy of ranibizumab (RBZ), bevacizumab (BVZ) and aflibercept (AFB) is comparable in ne...
Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) are common reti...
Nasser G Alsaedi,1,2 Ruba M Alselaimy,3 Abdulaziz A Alshamrani,1 Muhammed AlAjmi,4 Rajiv Khandekar,1...
Background/aims Aflibercept is an approved therapy for neovascular age-related macular degeneration ...
OBJECTIVE: Although a reduced aflibercept (2.0mg) injection frequency relative to the approved dosin...
Intravitreal antivascular endothelial growth factor (VEGF) agents are widely used to treat ocular co...
Contains fulltext : 201379.pdf (publisher's version ) (Open Access
Purpose: This study was designed to assess the functional and anatomic outcomes of intravitreal afli...
Introduction Age-related macular degeneration (AMD) is an eye disease that can cause severe vision l...
International audienceThe current use of bevacizumab for age-related macular degeneration is mainly ...
PURPOSE Ranibizumab and aflibercept are both approved for the treatment of neovascular age-related ...
Noriko Miyamoto,1,2 Michiko Mandai,1,3 Hiroshi Kojima,1,2 Takanori Kameda,1,2 Masataka Shimozono,1,2...
Age-related macular degeneration (AMD) is a blinding disease placing considerable burden on society ...
Purpose. To evaluate the economic and clinical results of the aflibercept and ranibizumab angiogenes...
ABSTRACT Purpose: The present study compared the efficacy of aflibercept for neovascular age-relate...
Since the efficacy of ranibizumab (RBZ), bevacizumab (BVZ) and aflibercept (AFB) is comparable in ne...
Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) are common reti...
Nasser G Alsaedi,1,2 Ruba M Alselaimy,3 Abdulaziz A Alshamrani,1 Muhammed AlAjmi,4 Rajiv Khandekar,1...
Background/aims Aflibercept is an approved therapy for neovascular age-related macular degeneration ...
OBJECTIVE: Although a reduced aflibercept (2.0mg) injection frequency relative to the approved dosin...
Intravitreal antivascular endothelial growth factor (VEGF) agents are widely used to treat ocular co...
Contains fulltext : 201379.pdf (publisher's version ) (Open Access